Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage

DNA Repair

Volumn 42, Issue , 2016, Pages 63-71

  Karimian, Ansar ^a,b   Ahmadi, Yasin ^a,b   Yousefi, Bahman ^a,b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Cell cycle; DNA damage; P21

Indexed keywords

P53R2 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

APOPTOSIS; CELL CYCLE REGULATION; DNA DAMAGE; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; CELL CYCLE; CYTOPLASM; GENETICS; METABOLISM;

ANIMALS; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPLASM; DNA DAMAGE; HUMANS; TRANSCRIPTION, GENETIC;

EID: 84964853264     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2016.04.008     Document Type: Review

References (114)

1. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9(6):400-414.
2. Gartel A.L. Is p21 an oncogene?. Mol. Cancer Ther. 2006, 5(6):1385-1386.
3. Bertoli C., Skotheim J.M., de Bruin R.A.M. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 2013, 14(8):518-528.
4. Zaldua N., Llavero F., Artaso A., Gálvez P. Rac1/p21-activated kinase pathway controls retinoblastoma protein phosphorylation and E2F transcription factor activation in B lymphocytes. FEBS J. 2016, 283(4):647-661.
5. Wang Y., Fisher J.C., Mathew R., Ou L., Otieno S., Sublet J., et al. Intrinsic disorder mediates the diverse regulatory functions of the Cdk inhibitor p21. Nat. Chem. Biol. 2011, 7(4):214-221.
6. Hoffman W.H., Biade S., Zilfou J.T., Chen J. Subcellular localisation of cyclin D1 protein in colorectal tumours is associated with p21WAF1/CIP1 expression and correlates with patient survival. J. Biol. Chem. 2002, 277(5):3247-3257.
7. Yousefi B., Rahmati M., Ahmadi Y. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life Sci. 2014, 99(1):14-17.
8. Roninson I.B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002, 179(1):1-14.
9. Hsieh Y.J., Hwu L., Chen Y.C., Ke C.C., Chen F.D., Wang H.E., et al. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivomolecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor. J. Nucl. Med. 2014, 55(4):678-685.
10. Kroker A.J., Bruning J.B. p21 exploits residue Tyr151 as a tether for high-affinity PCNA binding. Biochemistry 2015, 54(22):3483-3493.
11. Prives C., Gottifredi V. The p21 and PCNA partnership: a new twist for an old plot. Cell Cycle 2008, 7(24):3840-3846.
12. Soria G., Gottifredi V. PCNA-coupled p21 degradation after DNA damage: the exception that confirms the rule?. DNA Repair 2010, 9(4):358-364.
13. Wu Z., Zheng S., Yu Q. The E2F family and the role of E2F1 in apoptosis. Int. J. Biochem. Cell Biol. 2009, 41(12):2389-2397.
14. Jung Y.-S., Qian Y., Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell. Signal. 2010, 22(7):1003-1012.
15. Bitomsky N., Conrad E., Moritz C., Polonio-Vallon T., Sombroek D., Schultheiss K., et al. Autophosphorylation and Pin1 binding coordinate DNA damage-induced HIPK2 activation and cell death. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(45):E4203-12.
16. Mullan P., Quinn J., Harkin D. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006, 25(43):5854-5863.
17. Seoane J., Le H.-V., Shen L., Anderson S.A., Massagué J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004, 117(2):211-223.
18. Meng X.M., Chung A.C., Lan H.Y. Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin. Sci. (Lond.) 2013, 124(4):243-254.
19. Pavlides S.C., Lecanda J., Daubriac J., Pandya U.M., Gama P., Blank S., et al. TGF-β activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 fornormal endometrial growth. Cell Cycle 2016, 15(7):931-947.
20. Lee E.W., Lee M.S., Camus S., Ghim J., Yang M.R., Oh W., et al. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J. 2009, 28(14):2100-2113.
21. Yagi A., Hasegawa Y., Xiao H., Haneda M., Kojima E., Nishikimi A., et al. GADD34 induces p53 phosphorylation and p21/WAF1 transcription. J. Cell. Biochem. 2003, 90(6):1242-1249.
22. Xu H., Wang Z., Jin S., Hao H., Zheng L., Zhou B., et al. Dux4 induces cell cycle arrest at G1 phase through upregulation of p21 expression. Biochem. Biophys. Res. Commun. 2014, 446(1):235-240.
23. Hydbring P., Malumbres M., Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat. Rev. Mol. Cell Biol. 2016, (April). (Epub ahead of print). 10.1038/nrm.2016.27.
24. Wu S., Cetinkaya C., Munoz-Alonso M.J., Von Der Lehr N., Bahram F., Beuger V., et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003, 22(3):351-360.
25. Choi W.-I., Kim M.-Y., Jeon B.-N., Koh D.-I., Yun C.-O., Li Y., et al. Role of promyelocytic leukemia zinc finger (PLZF) in cell proliferation and cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) gene repression. J. Biol. Chem. 2014, 289(27):18625-18640.
26. Naito M., Vongsa S., Tsukune N., Ohashi A., Takahashi T. Promyelocytic leukemia zinc finger mediates glucocorticoid-induced cell cycle arrest in the chondroprogenitor cell line ATDC5. Mol. Cell. Endocrinol. 2015, 417:114-123.
27. Hawkes W.C., Alkan Z. Delayed cell cycle progression from SEPW1 depletion is p53-and p21-dependent in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 2011, 413(1):36-40.
28. Hatfield D.L., Tsuji P.A., Carlson B.A., Gladyshev V.N. Selenium and selenocysteine: roles in cancer, health, and development. Trends Biochem. Sci. 2014, 39(3):112-120.
29. Jeong D.-W., Kim T.S., Chung Y.W., Lee B.J., Kim I.Y. Selenoprotein W is a glutathione-dependent antioxidant in vivo. FEBS Lett. 2002, 517(1):225-228.
30. Aachmann F.L., Fomenko D.E., Soragni A., Gladyshev V.N., Dikiy A. Solution structure of selenoprotein W and NMR analysis of its interaction with 14-3-3 proteins. J. Biol. Chem. 2007, 282(51):37036-37044.
31. Hawkes W.C., Wang T.T., Alkan Z., Richter B.D., Dawson K. Selenoprotein W modulates control of cell cycle entry. Biol. Trace Elem. Res. 2009, 131(3):229-244.
32. Bard-Chapeau E.A., Jeyakani J., Kok C.H., Muller J., Chua B.Q., Gunaratne J., et al. Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(6):2168-2173.
33. Nayak K.B., Kuila N., Mohapatra A.D., Panda A.K., Chakraborty S. EVI1 targets δNp63 and upregulates the cyclin dependent kinase inhibitor p21 independent of p53 to delay cell cycle progression and cell proliferation in colon cancer cells. Int. J. Biochem. Cell Biol. 2013, 45(8):1568-1576.
34. Palazzo E., Kellett M., Cataisson C., Gormley A., Bible P.W., Pietroni V., et al. The homeoprotein DLX3 and tumor suppressor p53 co-regulate cell cycle progression and squamous tumor growth. Oncogene 2015, [Epub ahead of print].
35. Bid H.K., Roberts R.D., Cam M., Audino A., Kurmasheva R.T., Lin J., Houghton P.J., Cam H. δNp63 promotes pediatric neuroblastoma and osteosarcoma by regulating tumor angiogenesis. Cancer Res. 2014, 74(1):320-329.
36. Raman M., Chen W., Cobb M. Differential regulation and properties of MAPKs. Oncogene 2007, 26(22):3100-3112.
37. Chen R.E., Thorner J. Function and regulation in MAPK signaling pathways: lessons learned from the yeast Saccharomyces cerevisiae. Biochim. Biophys. Acta 2007, 1773(8):1311-1340.
38. Aschner J.L., Aschner M. Nutritional aspects of manganese homeostasis. Mol. Aspects Med. 2005, 26(4):353-362.
39. Cheng J., Fu J., Zhou Z. The mechanism of manganese-induced inhibition of steroidogenesis in rat primary Leydig cells. Toxicology 2005, 211(1):1-11.
40. Zhao F., Zhang J.-B., Cai T.-J., Liu X.-Q., Liu M.-C., Ke T., et al. Manganese induces p21 expression in PC12 cells at the transcriptional level. Neuroscience 2012, 215:184-195.
41. Dehennaut V., Loison I., Boulay G., Van Rechem C., Leprince D. Identification of p21 (CIP1/WAF1) as a direct target gene of HIC1 (Hypermethylated In Cancer 1). Biochem. Biophys. Res. Commun. 2013, 430(1):49-53.
42. Fleuriel C., Touka M., Boulay G., Guérardel C., Rood B.R., Leprince D. HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Int. J. Biochem. Cell Biol. 2009, 41(1):26-33.
43. Janeckova L., Pospichalova V., Fafilek B., Vojtechova M., Tureckova J., Dobes J., et al. HIC1 tumor suppressor loss potentiates TLR2/NF-κB signaling and promotes tissue damage-associated tumorigenesis. Mol. Cancer Res. 2015, 13(7):1139-1148.
44. Van Rechem C., Boulay G., Pinte S., Stankovic-Valentin N., Guérardel C., Leprince D. Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Mol. Cell. Biol. 2010, 30(16):4045-4059.
45. Dehennaut V., Loison I., Boulay G., Van Rechem C., Leprince D. Identification of p21 (CIP1/WAF1) as a direct target gene of HIC1 (Hypermethylated In Cancer 1). Biochem. Biophys. Res. Commun. 2013, 430(1):49-53.
46. Wales M.M., Biel M.A., El Deiry W., Nelkin B.D., Issa J.-P., Cavenee W.K., et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat. Med. 1995, 1(6):570-577.
47. Guerardel C., Deltour S., Pinte S., Monte D., Begue A., Godwin A.K., et al. Identification in the human candidate tumor suppressor geneHIC-1 of a new major alternative TATA-less promoter positively regulated by p53. J. Biol. Chem. 2001, 276(5):3078-3089.
48. Dixit D., Sharma V., Ghosh S., Mehta V.S., Sen E. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell Death Dis. 2012, 3:e271.
49. Nemoto S., Fergusson M.M., Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 2004, 306(5704):2105-2108.
50. Chen W.Y., Wang D.H., Yen R.C., Luo J., Gu W., Baylin S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005, 123(3):437-448.
51. Stankovic-Valentin N., Deltour S., Seeler J., Pinte S., Vergoten G., Guérardel C., et al. An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol. Cell. Biol. 2007, 27:2661-2675.
52. Soldevilla B., Millán C.S., Bonilla F., Domínguez G. The TP73 complex network: ready for clinical translation in cancer?. Genes Chromosomes Cancer 2013, 52(11):989-1006.
53. Fontemaggi G., Gurtner A., Damalas A., Costanzo A., Higashi Y., Sacchi A., et al. δEF1 repressor controls selectively p53 family members during differentiation. Oncogene 2005, 24(49):7273-7280.
54. Bui T., Sequeira J., Wen T.C., Sola A., Higashi Y., Kondoh H., et al. ZEB1 links p63 and p73 in a novel neuronal survival pathway rapidly induced in response to cortical ischemia. PLoS One 2009, 4(2):e4373.
55. Hu F., Wang C., Du J., Sun W., Yan J., Mi D., et al. δEF1 promotes breast cancer cell proliferation through down-regulating p21 expression. Biochim. Biophys. Acta 2010, 1802(2):301-312.
56. Liu W., Monahan K.B., Pfefferle A.D., Shimamura T., Sorrentino J., Chan K.T., et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012, 21(6):751-764.
57. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(10):3329-3335.
58. Goodwin J.M., Svensson R.U., Lou H.J., Winslow M.M., Turk B.E., Shaw R.J. An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 andmetastatic potential. Mol. Cell 2014 Aug 7, 55(3):436-450.
59. Zeng P.-Y., Berger S.L. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res. 2006, 66(22):10701-10708.
60. Lai D., Chen Y., Wang F., Jiang L., Wei C. LKB1 controls the pluripotent state of human embryonic stem cells. Cell. Reprogr. 2012, 14(2):164-170.
61. Herrmann J.L., Byekova Y., Elmets C.A., Athar M. Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett. 2011, 306(1):1-9.
62. Kollarovic G., Studencka M., Ivanova L., Lauenstein C., Heinze K., Lapytsko A., et al. To senesce or not to senesce: how primary human fibroblasts decide their cell fate after DNA damage. Aging (Albany NY) 2016, 8(January (1)):158-177.
63. Koutsodontis G., Tentes I., Papakosta P., Moustakas A., Kardassis D. Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21 WAF1/Cip1 gene by the p53 tumor suppressor protein. J. Biol. Chem. 2001, 276(31):29116-29125.
64. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120(4):513-522.
65. Lagger G., Doetzlhofer A., Schuettengruber B., Haidweger E., Simboeck E., Tischler J., et al. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol. Cell. Biol. 2003, 23(8):2669-2679.
66. Kim H.-S., Heo J.-I., Park S.-H., Shin J.-Y., Kang H.-J., Kim M.-J., et al. Transcriptional activation of p21WAF1/CIP1 is mediated by increased DNA binding activity and increased interaction between p53 and Sp1 via phosphorylation during replicative senescence of human embryonic fibroblasts. Mol. Biol. Rep. 2014, 41(4):2397-2408.
67. Morton J.P., Jamieson N.B., Karim S.A., Athineos D., Ridgway R.A., Nixon C., et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 2010, 139(2):586-597. e6.
68. Takeda I., Maruya S., Shirasaki T., Mizukami H., Takahata T., Myers J.N., et al. Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007, 98:890-899.
69. Guterres F.A., Martinez G.R., Rocha M.E., Winnischofer S.M. Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells byactivation of p53/p21 pathway. Exp. Cell Res. 2013, 319:2977-2988.
70. Agarwal B., Halmos B., Feoktistov A.S., Protiva P., Ramey W.G., Chen M., et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 2002, 23:521-528.
71. Denoyelle C., Albanese P., Uzan G., Hong L., Vannier J.P., Soria J., Soria C. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal. 2003, 115:327-338.
72. Koyuturk M., Ersoz M., Altiok N. Simvastatin induces apoptosis in human breast cancer cells:p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett. 2007, 250:220-228.
73. Ivanov I., Heydeck D., Hofheinz K., Roffeis J., O'Donnell V.B., Kuhn H., et al. Molecular enzymology of lipoxygenases. Arch. Biochem. Biophys. 2010, 503(2):161-174.
74. Pidgeon G.P., Lysaght J., Krishnamoorthy S., Reynolds J.V., O'Byrne K., Nie D., et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev. 2007, 26(3-4):503-524.
75. Glasgow W.C., Hui R., Everhart A.L., Jayawickreme S.P., Angerman-Stewart J., Han B.B., et al. The linoleic acid metabolite, (13S)-hydroperoxyoctadecadienoic acid, augments the epidermal growth factor receptor signaling pathway by attenuation of receptor dephosphorylation. Differential response in syrian hamster embryo tumor suppressor phenotypes. J. Biol. Chem. 1997, 272:19269-19276.
76. Gilbert B., Ahmad K., Roos J., Lehmann C., Chiba T., Ulrich-Rückert S., et al. 5-Lipoxygenase is a direct p53 target gene in humans. Biochim. Biophys. Acta 2015, 1849(August (8)):1003-1016.
77. Yang M.H., Zang Y.S., Huang H., Chen K., Li B., Sun G.Y., Zhao X.W. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Curr. Cancer Drug Targets 2014, 14(6):557-566.
78. Jadhav V., Ray P., Sachdeva G., Bhatt P. Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines. Life Sci. 2016, 148:41-52.
79. Jomova K., Jenisova Z., Feszterova M., Baros S., Liska J., Hudecova D., et al. Arsenic: toxicity, oxidative stress and human disease. J. Appl. Toxicol. 2011, 31(2):95-107.
80. Ma Z.B., Xu H.Y., Jiang M., Yang Y.L., Liu L.X., Li Y.H. Arsenic trioxide induces apoptosis of human gastrointestinal cancer cells. World J. Gastroenterol. 2014, 20(18):5505-5510.
81. Chow S.K., Chan J.Y., Fung K.P. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J. Cell. Biochem. 2004 Sep 1, 93(1):173-187.
82. Kang Y.H., Lee S.J. Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. Oncol. Rep. 2008, 20(3):637-643.
83. Liu Z.M., Huang H.S. As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Cell Signal. 2006, 18(February (2)):244-255.
84. Liua Zi-Miao, Huanga Huei-Sheng As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sitesto stimulate p21WAF1/CIP1 expression in human epidermoid. Cell Signal. 2006, 18:244-255.
85. Yu M., Wang H., Xu Y., Yu D., Li D., Liu X., Du W. Insulin-like growth factor-1 (IGF-1) promotes myoblast proliferation and skeletal muscle growth of embryonic chickens via the PI3K/Akt signalling pathway. Cell Biol. Int. 2015, 39(8):910-922.
86. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004, 95(1):7-11.
87. Huang X., Zhang S., Qi H., Wang Z., Chen H.W., Shao J., Shen J. JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation. Biochim. Biophys. Acta 2015, 1853(10):2286-2295.
88. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000, 404(6773):42-49.
89. Chang L., Zhou B., Hu S., Guo R., Liu X., Jones S.N., et al. ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(47):18519-18524.
90. Pontarin G., Ferraro P., Håkansson P., Thelander L., Reichard P., Bianchi V. p53R2-dependent ribonucleotide reduction provides deoxyribonucleotides in quiescent human fibroblasts in the absence of induced DNA damage. J. Biol. Chem. 2007, 282(23):16820-16828.
91. Zhang K., Wu J., Wu X., Wang X., Wang Y., Zhou N., et al. p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest. Mol. Cancer Ther. 2011, 10(2):269-278.
92. Liesa M. Shirihai OS Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013, 17(4):491-506.
93. Garrett M.D. Cell cycle control and cancer. Curr. Sci. 2001, 81(5):515-522.
94. Deng S., Tang S., Dai C., Zhou Y., Yang X., Li D., Xiao X. P21 Waf1/Cip1 plays a critical role in furazolidone-induced apoptosis in HepG2 cells through influencing the caspase-3 activation and ROS generation. Food Chem. Toxicol. 2016, 88(February):1-12.
95. Xue L., Zhou B., Liu X., Heung Y., Chau J., Chu E., et al. Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation. Cancer Res. 2007, 67(1):16-21.
96. Neri L.M., Cani A., Martelli A.M., Simioni C., Junghanss C., Tabellini G., et al. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia 2014, 28(April (4)):739-748.
97. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. PI3K/Akt signaling pathway and cancer. Cancer Treat. Rev. 2004, 30:193-204.
98. Luo H.R., Hattori H., Hossain M.A., Hester L., Huang Y., Lee-Kwon W., Donowitz M., Nagata E., Snyder S.H. Akt as a mediator of cell death. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11712-11717.
99. Franke T.F., Hornik C., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998.
100. Kumar A., Purohit R. Cancer associated E17K mutation causes rapid conformational drift in AKT1 pleckstrin homology (PH) domain. PLoS One 2013, 8(May (5)):e64364.
101. Nicholson K.M., Anderson N. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002, 14:381-395.
102. Maillet M., van Berlo J.H., Molkentin J.D. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat. Rev. Mol. Cell Biol. 2013, 14(1):38-48.
103. Peng X.D., Xu P., Chen M.L., Hahn-Windgassen A., Skeen J., Jacobs J.S.D., et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 2003, 17:1352-1365.
104. Eser S., Schnieke A., Schneider G., Saur D. Oncogenic KRAS signalling in pancreatic cancer. Br. J. Cancer 2014, 111(August (5)):817-822.
105. Zhang X., Ma L., Qi J., Shan H., Yu W., Gu Y. MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy. Mol. Cell. Biochem. 2015, 410(December (1-2)):101-110.
106. Vanhaesebroeck B., Alessi D. The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J 2000, 346:561-576.
107. Wick M.J., Dong L., Riojas R.A., Ramos F.J., Liu F. kinase-1. Mechanism of phosphorylation of protein kinase B/Akt by a constitutively active 3-phosphoinositide-dependent protein. J. Biol. Chem. 2000, 275:40400-40406.
108. Risso G., Blaustein M., Pozzi B., Mammi P., Srebrow A. Akt/PKB: one kinase, many modification. Biochem. J 2015, 468(June (2)):203-214.
109. Zhou B.L.Y., Xia W., Spohn B., Lee M., Hung M. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 2001, 3:245-252.
110. Warfel N.A., El-Deiry W.S. p21WAF1 and tumourigenesis: 20 years after. Curr. Opin. Oncol. 2013, 25(January (1)):52-58.
111. Kreis N.N., Louwen F., Yuan J. Less understood issues: p21Cip1 in mitosis and its therapeutic potential. Oncogene 2015, 34(April (14)):1758-1767.
112. Gehen S.C., Vitiello P.F., Bambara R.A., Keng P.C., O'Reilly M.A. Downregulation of PCNA potentiates p21-mediated growth inhibition in response to hyperoxia. Am. J. Physiol. 2007, 292(3):L716-L724.
113. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., Hung M.C. Cytoplasmic localization of p21cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 2001, 3:245-252.
114. Kreis N.N., Louwen F., Zimmer B., Yuan J. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition. Oncotarget 2015, 6(9):6611-6626.